1. Continued use of semaglutide or tirzepatide leads to greater weight loss and improved glycemic control.
2. Tirzepatide users experienced greater weight loss compared with semaglutide users.
3. Patients who remained on therapy had a higher likelihood of achieving at least 10% weight loss.
4. The study provides insights into medication continuation and dosing in obesity and prediabetes management.

Source: Obesity